Response-Adaptive Designs in Phase III Clinical Trials

2008 ◽  
pp. 33-53
Author(s):  
Atanu Biswas ◽  
Uttam Bandyopadhyay ◽  
Rahul Bhattacharya
Keyword(s):  
Clinical Trials ◽  
Adaptive Designs ◽  
Phase Iii ◽  
Phase Iii Clinical Trials ◽  
Response Adaptive Designs

Bayesian optimal response-adaptive design for binary responses using stopping rule

2016 ◽  
Vol 27 (3) ◽  
pp. 891-904 ◽  
Author(s):  
Fumiyasu Komaki ◽  
Atanu Biswas
Keyword(s):  
Clinical Trials ◽  
Adaptive Design ◽  
Real Data ◽  
Adaptive Designs ◽  
Phase Iii ◽  
Data Set ◽  
Binary Responses ◽  
Phase Iii Clinical Trials ◽  
Number Of Patients ◽  
Response Adaptive Designs

Response-adaptive designs are used in phase III clinical trials to allocate a larger number of patients to the better treatment arm. Optimal designs are explored in the recent years in the context of response-adaptive designs, in the frequentist view point only. In the present paper, we propose some response-adaptive designs for two treatments based on Bayesian prediction for phase III clinical trials. Some properties are studied and numerically compared with some existing competitors. A real data set is used to illustrate the applicability of the proposed methodology where we redesign the experiment using parameters derived from the data set.

Rome I versus Rome II; Overlap in patients enrolled in tegaserod phase III clinical trials for irritable bowel syndrome (IBS)

2001 ◽  
Vol 120 (5) ◽  
pp. A284-A284
Author(s):  
B NAULT ◽  
S SUE ◽  
J HEGGLAND ◽  
S GOHARI ◽  
G LIGOZIO ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Irritable Bowel Syndrome ◽  
Phase Iii ◽  
Phase Iii Clinical Trials ◽  
Irritable Bowel ◽  
Rome I

Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials

2001 ◽  
Vol 28 (6) ◽  
pp. 620-625 ◽  
Author(s):  
Pierre Falardeau ◽  
Pierre Champagne ◽  
Patrick Poyet ◽  
Claude Hariton ◽  
[Eacute]ric Dupont
Keyword(s):  
Clinical Trials ◽  
Phase Iii ◽  
Phase Iii Clinical Trials ◽  
Naturally Occurring ◽  
Antiangiogenic Drug
Sign in / Sign up

Export Citation Format

Share Document